CoChat

Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial

Open access

Published version of a preprint

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Purpose: To perform real-time whole genome sequencing (WGS) and RNA sequencing (RNASeq) of advanced pancreatic ductal adenocarcinoma (PDAC) to identify predictive mutational and transcriptional features for better treatment selection. Experimental Design: Patients with advanced PDAC were prospectively recruited prior to first-line combination chemotherapy. Fresh tumor tissue was acquired by image-guided percutaneous core biopsy for WGS and RNASeq. Laser capture microdissection was performed for all cases. Primary endpoint was feasibility to report WGS results prior to first disease assessment CT scan at 8 weeks. The main secondary endpoint was discovery of patient subsets with predictive mutational and transcriptional signatures. Results: Sixty-three patients underwent a tumor biopsy between December 2015 and June 2017. WGS and RNASeq were successful in 62 (98%) and 60 (95%), respectively. Genomic results were reported at a median of 35 days (range, 19–52 days) from biopsy, meeting the primary feasibility endpoint. Objective responses to first-line chemotherapy were significantly better in patients with the classical PDAC RNA subtype compared with those with the basal-like subtype (P = 0.004). The best progression-free survival was observed in those with classical subtype treated with m-FOLFIRINOX. GATA6 expression in tumor measured by RNA in situ hybridization was found to be a robust surrogate biomarker for differentiating classical and basal-like PDAC subtypes. Potentially actionable genetic alterations were found in 30% of patients. Conclusions: Prospective genomic profiling of advanced PDAC is feasible, and our early data indicate that chemotherapy response differs among patients with different genomic/transcriptomic subtypes. Clin Cancer Res; 24(6); 1344–54. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-2994

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 1

  1. Hidalgo, 2015 5–9, Palbociclib potentiates nab-paclitaxel efficacy in pancreatic ductal adenocarcinoma. [abastract]

Cited by

See all 679

Metadata

Authors
Aung, K. L., Fischer, S. E., Denroche, R. E., Jang, G.-H., Dodd, A., Creighton, S., Southwood, B., Liang, S.-B., Chadwick, D., Zhang, A., O'Kane, G. M., Albaba, H., Moura, S., Grant, R. C., Miller, J. K., Mbabaali, F., Pasternack, D., Lungu, I. M., Bartlett, J. M. S., Ghai, S., Lemire, M., Holter, S., Connor, A. A., Moffitt, R. A., Yeh, J. J., Timms, L., Krzyzanowski, P. M., Dhani, N., Hedley, D., Notta, F., Wilson, J. M., Moore, M. J., Gallinger, S., & Knox, J. J.
Affiliations
  • University Health Network (CA)
  • Ontario Institute for Cancer Research (CA)
  • Mount Sinai Hospital (CA)
  • University of North Carolina at Chapel Hill (US)
  • BC Cancer Agency (CA)
  • 1Wallace McCain Centre for Pancreatic Cancer, Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Corresponding author
Knox, Jennifer J.
Venue
Clinical Cancer Research
Published
2018-03-14
Volume
24
Issue
6
Pages
1344-1354
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2780727948
Cited by
618
References
48
Citations by year
2026: 48 · 2025: 75 · 2024: 73 · 2023: 85 · 2022: 76 · 2021: 117 · 2020: 71 · 2019: 52 · 2018: 17
FWCI
16.99
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • UNC Libraries
Funders
  • Ontario Institute for Cancer Research (OICR)
  • Canadian Cancer Society Research Institute (CCSRI) (702316)
  • Canadian Friends of Tel Aviv University (CFTAU)
  • HHS | NIH | National Cancer Institute (NCI) (CA193650)
  • Division of Cancer Prevention, National Cancer Institute (DCP, NCI) (CA199064)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Keywords
pancreatic ductal adenocarcinoma, precision oncology, whole genome sequencing, RNA sequencing, predictive biomarkers, classical subtype, basal-like subtype, first-line chemotherapy response, actionable genomic alterations, tumor biopsy, COMPASS trial
MeSH terms
Exome Sequencing, Adult, Aged, Clinical Trials as Topic, DNA Damage, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Neoplasm Staging, Pancreatic Neoplasms, Biomarkers, Tumor, Disease Progression, Disease Management, Genomics, GATA6 Transcription Factor, Precision Medicine, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-2994
The paper
Aung, K. L., Fischer, S. E., Denroche, R. E., Jang, G.-H., Dodd, A., Creighton, S., Southwood, B., Liang, S.-B., Chadwick, D., Zhang, A., O'Kane, G. M., Albaba, H., Moura, S., Grant, R. C., Miller, J. K., Mbabaali, F., Pasternack, D., Lungu, I. M., Bartlett, J. M. S., . . . Knox, J. J. (2018). Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-2994

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.